Idec Pharmaceuticals Matches Fourth-Quarter Expectations
Chris Frankie
01/29/01 - 06:05 PM EST
| Earnings Scorecard |
| Actual | Estimated* | Year-Ago |
| $0.12 | $0.12 | $0.05
|
 |
Idec Pharmaceuticals (IDPH Quote) said Monday that it met Wall Street's earnings expectations for the fourth quarter.
The biopharmaceutical company, which is based in San Diego, said it earned $20.4 million, or 12 cents a share, up from $7.7 million, or 5 cents a share in the year-ago period. Ten analysts polled by
First Call/Thomson Financial were calling for the company to earn 12 cents a share in the period.
Revenue increased to $45.8 million from $32 million in the equivalent period last year.
Sales of Rituxan, which is copromoted in the U.S. by Idec and
Genetech (DNA Quote), totaled $134 million for the fourth quarter. Sales from the drug, which is used to treat non-Hodgkin's lymphoma, was up from the $72.2 million in the equivalent period last year.
Shares of Idec gained $3.50, or 5.5%, to $66.81 in the regular session
Nasdaq, but slipped slightly to $66.50 in recent after-hours
Island trading.
